CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • Ȳ¼º±Ô
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °£Àå, °£¾Ï
  • Á÷ À§: ±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
203 (±¹³»)KCI À§ºÎºÐÀýÁ¦¼ú ÈÄ ¹ß»ýÇÏ´Â ´ãµµ È®Àå ¹× ´ã¼®ÁõÀÇ ÀÓ»óÀû ÀÇÀÇ
202 (±¹¿Ü)SCI Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma
201 (±¹¿Ü)SCI Peroral endoscopic myotomy for esophageal muscular ring
200 (±¹³»)SCOPUS Optimal methods for the management of iatrogenic colonoscopic perforation
199 (±¹¿Ü)SCIE Genetic variants in 3¡¯-UTRs of methylenetetrahydrofolate reductase (MTHFR) predict colorectal cancer susceptibility in Korean
198 (±¹¿Ü)SCI Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study
197 (±¹³»)SCOPUS Is the Endoscopic Grasp-and-Traction Device Useful for Endoscopic Submucosal Dissection in Treating Early Gastric Cancer?
196 (±¹¿Ü)SCI Nomograms forPredictingOutcomesafter Chemoembolization inPatientswith Nonmetastatic Hepatocellular Carcinoma
195 (±¹¿Ü)SCI Prevention of Hepatocellular Carcinoma: Beyond Hepatitis B Vaccination
194 (±¹¿Ü)SCI Risk stratification and management of non-curative resection after endoscopic submucosal dissection for early gastric cancer.
ÀÌÀüÆäÀÌÁö À̵¿ 21 22 23 24 25 26 27 28 29 30 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729